Otviciclib
Otviciclib (Compound 86) is a CDK inhibitor. Otviciclib has potent anti-proliferative activity against solid tumor cells (such as HCT116, NCIH82 and DU145 cells) with no significant toxicity to normal cells, and effectively induces the G2/M phase cells arrest and apoptosis. Otviciclib has a broad-spectrum anticancer activity, such as colon, pancreatic and lung cancer[1].
Product Specifications
CAS Number
2228039-87-8
UNSPSC
12352005
Target
Apoptosis; CDK
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
O=C1N=C(CC2=CC=C(NC(CN(CC)CC)=O)C=C2)NC3=C1C(N(C)C)=NN3C4=C(C=C(S(=O)(N)=O)C=C4Cl)Cl
Molecular Formula
C26H30Cl2N8O4S
Molecular Weight
621.54
References & Citations
[1]Wunderlich W, et al. 3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors. WO2018099952A1. 2018-06-07.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD81 / TAPA-1 (1.3.3.22), CF488A conjugate, 0.1mg/mL
P21 / WAF1 (WA-1), CF640R conjugate, 0.1mg/mL
CD21 (Mature B-Cell & Follicular Dendritic Cell Marker) (CR2/1952), CF640R conjugate, 0.1mg/mL
Ep-CAM / CD326 (VU-1D9), CF740 conjugate, 0.1mg/mL
